CN113332162A - protamine-PDRN compound, composition and application in preparation of skin care product - Google Patents
protamine-PDRN compound, composition and application in preparation of skin care product Download PDFInfo
- Publication number
- CN113332162A CN113332162A CN202110436323.5A CN202110436323A CN113332162A CN 113332162 A CN113332162 A CN 113332162A CN 202110436323 A CN202110436323 A CN 202110436323A CN 113332162 A CN113332162 A CN 113332162A
- Authority
- CN
- China
- Prior art keywords
- protamine
- pdrn
- composition
- acne
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 206010000496 acne Diseases 0.000 claims abstract description 84
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 78
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 7
- 230000002087 whitening effect Effects 0.000 claims abstract description 7
- 102000007327 Protamines Human genes 0.000 claims description 31
- 108010007568 Protamines Proteins 0.000 claims description 31
- 229940048914 protamine Drugs 0.000 claims description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 11
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 11
- 229920002125 Sokalan® Polymers 0.000 claims description 11
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 11
- 229960001631 carbomer Drugs 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 210000004209 hair Anatomy 0.000 claims description 8
- 229960005323 phenoxyethanol Drugs 0.000 claims description 8
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 7
- 230000008439 repair process Effects 0.000 claims description 7
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 7
- 229960000401 tranexamic acid Drugs 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 229960003966 nicotinamide Drugs 0.000 claims description 6
- 235000005152 nicotinamide Nutrition 0.000 claims description 6
- 239000011570 nicotinamide Substances 0.000 claims description 6
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims description 5
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 5
- 229940099552 hyaluronan Drugs 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims description 5
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 5
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 4
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 4
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 4
- 108010087806 Carnosine Proteins 0.000 claims description 4
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 4
- 230000003796 beauty Effects 0.000 claims description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 4
- 229940044199 carnosine Drugs 0.000 claims description 4
- 229960003993 chlorphenesin Drugs 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 4
- 230000000472 traumatic effect Effects 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 206010011732 Cyst Diseases 0.000 claims description 3
- 206010037888 Rash pustular Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 230000003385 bacteriostatic effect Effects 0.000 claims description 3
- 208000031513 cyst Diseases 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000029561 pustule Diseases 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 208000035874 Excoriation Diseases 0.000 claims description 2
- 206010016936 Folliculitis Diseases 0.000 claims description 2
- 206010017553 Furuncle Diseases 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 238000005299 abrasion Methods 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000003266 anti-allergic effect Effects 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000490 cosmetic additive Substances 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 51
- 230000000694 effects Effects 0.000 abstract description 29
- 241000186427 Cutibacterium acnes Species 0.000 abstract description 11
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 10
- 230000012010 growth Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 210000004927 skin cell Anatomy 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 43
- 238000012360 testing method Methods 0.000 description 26
- 230000028327 secretion Effects 0.000 description 12
- 241000700198 Cavia Species 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 231100000241 scar Toxicity 0.000 description 7
- 244000068988 Glycine max Species 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010039792 Seborrhoea Diseases 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000013022 formulation composition Substances 0.000 description 3
- 229940014041 hyaluronate Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000037312 oily skin Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 206010070835 Skin sensitisation Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 231100000370 skin sensitisation Toxicity 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000922 anti-bactericidal effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention particularly relates to a protamine-PDRN compound, a composition and application in preparation of skin care products. The invention provides a protamine-PDRN compound which has the effect of inhibiting the growth of propionibacterium acnes. The invention further provides a product for treating acne and acne marks based on the protamine-PDRN compound, wherein the product comprises the protamine-PDRN compound, an effective polypeptide and other matrix components. The product is applied to human skin, has good effects of controlling oil, treating acne, improving acne marks and whitening, and can fundamentally nourish skin cells and improve the metabolism level of the skin cells. Has no toxic and side effects on human body safety, has extremely high biological safety, and provides preparation and application methods thereof.
Description
Technical Field
The invention belongs to the technical field of functional skin care products, and particularly relates to a protamine-PDRN compound, a composition and application in preparation of a skin care product.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
Acne, also known as acne and comedo, is a common chronic inflammatory skin disease which is developed in oily skin and is suitable for teenagers aged 13 to 24 years, mainly occurs in the face and the back, is easy to generate inflammatory reaction to cause large skin pores, scars and pigmentation, seriously influences the external image, confidence and social activities of the teenagers, and causes unnecessary psychological burden. Nowadays, with the change of dietary structure and life style and the increase of mental stress caused by the increase of pressure on life, work and study, the incidence age of acne also tends to increase, and the incidence rate of acne in people of about 30 years old is higher and higher. Acne is caused mainly by hyperseborrhea due to elevated testosterone levels in the body, dyskeratosis of the pilosebaceous canal, blockage, bacterial infection, inflammatory reaction, and the like. Propionibacterium acnes is a gram-positive G+Anaerobic bacteria (Propionibacterium acnes), a normal flora that often colonize hair follicles and sebaceous glands in human skin. When acne symptoms appear on the skin, the increase of sebum secretion leads to the growth and reproduction of a large amount of P.acnes, metabolizes a large amount of free fatty acid components, further leads the skin to become infected and inflammatory reaction, and causes vicious circle, so that the probability of acne generation of people with oily skin is higher.
The small molecular oligopeptide mainly comprises two to ten amino acids, can promote cell growth, differentiation, reconstruction and repair, fundamentally improve and repair skin injury, has obvious effects of wrinkle removal, aging resistance, whitening, freckle removal and the like, is an important component of an efficacy type cosmetic, and has extremely high use safety, for example: palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, carnosine, tripeptide-1 and copper peptide have good anti-inflammatory effect, and nonapeptide-1 has good whitening effect. Protamine is a basic protein rich in basic amino acids and present in mature fish sperm, and is widely used for treating hemorrhage caused by excessive heparin injection in clinic. Protamine is essentially a cationic polypeptide, which has excellent cell penetration effect, researches show that protamine has broad-spectrum antibacterial activity, particularly gram-positive bacteria, is a natural sterilization and preservative, can be used as a preservative of high-end food, has high biological safety because the protamine is completely composed of natural amino acid, and is safe and harmless to human bodies when in use, and the dosage is not limited. Compared with antibiotics, the antibacterial peptide is not easy to cause drug resistance of bacteria, and is an excellent antibiotic substitute.
PDRN (polydeoxyribonucleotides), polydeoxyribonucleotides, can accelerate DNA synthesis, and has the repair effects of sun screening, inflammation diminishing, cell regeneration promotion, tissue repair promotion, wound healing promotion, scar formation reduction, pore repair, wrinkle removal, ultraviolet damage resistance and the like as natural skin protective agents and repair agents. For example, PDRN infants are now becoming a hot product for the cosmetic market. In the field of gene therapy, protamine can be combined with DNA through electrostatic interaction to form a compound serving as a gene vector, so that the biocompatibility is good, the cell penetrability of the DNA can be enhanced, and the using effect is enhanced.
At present, products with skin care effects of controlling oil, shrinking pores, treating acne, repairing scars and the like comprise traditional Chinese medicine/plant extracts, antibiotics, chemically synthesized small molecules and the like, for example: patent CN110643598A provides a method for preparing yeast DNA material for promoting skin scar healing and pore shrinkage, which uses a gene gun (Bio-Jet molecular atomizer) to drive DNA molecules into skin, however, the method needs to be completed in professional organization, which limits the application range; patents CN102716380B, CN105832940A, CN109330953A adopt several traditional Chinese medicine/plant extracts; patent CN110269898A uses salicylic acid, clindamycin. The traditional Chinese medicine product is added with a plurality of plant extracts, the structure of active ingredients is undefined, the chemical components are complex, the content of the active ingredients is low, the action mechanism is undefined, the steps of extracting the active ingredients from the plants are complicated, and the content and the action effect of the active ingredients are easily influenced by different producing areas and different year sources; the oral administration of zinc sulfate or zinc gluconate is easy to cause gastrointestinal irritation, and adverse reactions such as nausea, vomiting, constipation and the like are caused; the long-term use of antibiotic components can easily cause the drug resistance of bacteria, reduce the curative effect and fail to achieve the curative effect; and some products are easy to generate side effects such as allergy and the like due to the difference of skin sensibility among individuals. Meanwhile, the following are clearly specified in the technical specifications for cosmetic safety 2015 edition: the effective components with bactericidal effect in the product for treating facial acne are as follows: tretinoin, tretinoin and isotretinoin are forbidden, and the use amount of salicylic acid is limited due to skin injury; the oral products for treating acne are easy to cause adverse reactions after being taken for a long time, so that extensive research institutions and manufacturers of medicines and skin care products are required to actively develop new structural components and/or unit types which have the acne treatment effect and are convenient to use.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, and provides a beauty skin care product for treating acne and acne marks, which is simple in preparation process, clear in action, safe and free from toxic and side effects, and a preparation method and an application method thereof, aiming at the formation mechanism of acne and the characteristic that skin is easy to scar after acne is cured, and taking protamine, PDRN and anti-inflammatory polypeptide which take natural amino acid and nucleotide as structural composition units as main components.
Based on the technical effects, the invention provides the following technical scheme:
in a first aspect of the invention, a protamine-PDRN complex is provided, wherein the ratio of protamine to PDRN in the complex is from 10:1 to 1: 10.
Acne is a common skin disease, the occurrence of which is closely related to propionibacterium acnes, which is a common parasitic bacterium inside the pilosebaceous glands of human bodies. When secretion in the pilosebaceous gland is increased and is not discharged smoothly, a large amount of culture medium of propionibacterium acnes can be caused. Propionibacterium acnes will multiply and a series of symptoms of acne will appear. Such as acne, papules, erythematous pustular nodulosis, even baldness, scars, and the like. The protamine-PDRN compound has the effect of inhibiting the growth of propionibacterium acnes, and compared with the traditional antibiotic medicine, the protamine-PDRN compound has higher affinity to a human body and is safer to use.
Further, the protamine-PDRN complex of the present invention, in combination with other active polypeptides and skin care active ingredients, and skin care product base, provides a more skin care composition, and therefore, in a second aspect of the present invention, a composition is provided, which comprises at least protamine, PDRN and other functional polypeptides, wherein the protamine and PDRN are the protamine-PDRN complex of the first aspect.
The composition may be provided in the form of one or more of an emulsion, a serum, a lotion, a cream, a powder, a cream, a gel, a dressing, based on the conventional selection of skin care bases in the art, and thus, in the third aspect of the present invention, the use of the composition of the second aspect in the preparation of a skin care product is provided.
In a fourth aspect of the invention, there is provided a care product for acne or acne marks, said care product comprising a protamine-PDRN complex according to the first aspect.
The beneficial effects of one or more technical schemes are as follows:
(1) the invention provides a beauty skin care product for treating acne and acne mark and a preparation and application method thereof aiming at the formation mechanism of acne and the easy scar generation of skin after the acne is cured.
(2) The protamine, PDRN and polypeptide which are selected as raw materials are two natural components which are necessary for human bodies, safe to human bodies, free of toxic and side effects and free of irritation, allergy and drug resistance: the composition is composed of amino acid and nucleotide, and has extremely high biological safety.
(3) The invention applies the cationic peptide protamine to the product for treating acne, the protamine has excellent bactericidal effect as a cationic polypeptide, and the bactericidal activity of the protamine can adjust the colonizing flora on the skin surface.
(4) According to the invention, protamine and PDRN with negative charges form an ionic bond through electrostatic interaction to form a protamine-PDRN compound, protamine has a large amount of positive charges and can be combined with negative charges on the surface of a cell membrane, the permeability of the cell membrane is enhanced, the transdermal absorption effect of PDRN is obviously enhanced, and the bioavailability of PDRN is improved.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, are included to provide a further understanding of the invention, and are incorporated in and constitute a part of this specification, illustrate exemplary embodiments of the invention and together with the description serve to explain the invention and not to limit the invention.
FIG. 1 is the average reduction in skin oil secretion described in example 9.
FIG. 2 shows the effect of the product of example 4 on removing pimples.
FIG. 3 shows the therapeutic effect of the product of example 5 on removing pimples.
Detailed Description
It is to be understood that the following detailed description is exemplary and is intended to provide further explanation of the invention as claimed. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of exemplary embodiments according to the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise.
As described in the background art, the existing products with skin care effects of treating acne, repairing scars and the like contain more medicinal components, so that the use of the products has risks, and in order to solve the technical problems, the protamine-PDRN complex and the application of the protamine-PDRN complex in skin care products are provided.
In a first aspect of the invention, a protamine-PDRN complex is provided, wherein the ratio of protamine to PDRN in the complex is from 10:1 to 1: 10.
Preferably, the molecular weight of the PDRN is 5-50 ten thousand;
preferably, the protamine is one of monoprotamine, biprotamine and tripprotamine;
preferably, the protamine to PDRN ratio is 1.5:1 to 2.5: 1.
Preferably, the protamine-PDRN complex is prepared as follows: mixing a protamine solution and a PDRN solution in proportion, stirring for a period of time to obtain a mixed solution, standing the mixed solution for a period of time, and drying to obtain the protamine-PDRN compound.
Further, the stirring time is 0.8-2 h, and specifically, the stirring time is preferably 1h or 1.5 h.
Further, the mixed solution is placed in a room temperature condition for standing, wherein the room temperature condition is not any room temperature condition, and specifically means a temperature condition of 18-25 ℃ under a standard atmospheric pressure.
Further, standing the mixed solution at room temperature for 0.8-1.2 h.
Further, the drying manner is one of vacuum drying, spray drying, flow drying or freeze drying. In a more preferred embodiment, the drying is performed by freeze-drying.
In a second aspect of the invention, a composition is provided, which at least comprises protamine, PDRN and other functional polypeptides, wherein the protamine and PDRN are the protamine-PDRN complex of the first aspect.
Preferably, the functional polypeptide is one or more of anti-wrinkle, anti-aging, repairing, whitening, anti-allergy, anti-inflammatory and antioxidant polypeptide.
Further, the functional polypeptide is any one or combination of any several of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, carnosine, tripeptide-1, copper peptide and nonapeptide-1.
Preferably, the composition further comprises other active ingredients, wherein the active ingredients comprise one or more of a moisturizing ingredient, a pH regulator, a whitening ingredient, a bacteriostatic ingredient, a cosmetic additive, a solubilizer and a surfactant.
Further, the composition also comprises the following components: carbomer, triethanolamine, low molecular weight hyaluronan, nicotinamide, tranexamic acid, propylene glycol, 1, 2-pentanediol, glycerol, phenoxyethanol, chlorphenesin, or sterile purified water.
In some embodiments with better effects of the invention, the compositions comprise the following components in percentage by weight: the addition amount of carbomer is 0.6-0.9%, the addition amount of triethanolamine is 0.5-0.9%, the addition amount of protamine-PDRN compound is 0.05-2%, the addition amount of anti-inflammatory polypeptide is 0.005-0.2%, the addition amount of low molecular weight hyaluronan is 0.05-0.1%, the addition amount of nicotinamide is 0.5-4%, the addition amount of tranexamic acid is 0.5-2%, the addition amount of 1, 2-pentanediol is 3-5%, the addition amount of glycerol is 2-12%, the addition amount of phenoxyethanol is 0.3-0.8%, and the addition amount of chlorphenesin is 0.03-0.1%.
In a third aspect of the invention, there is provided the use of a composition according to the second aspect in the manufacture of a skin care product.
Preferably, the skin care product is one or more of emulsion, essence, lotion, cream, powder, cream, gel and dressing.
Preferably, the skin care product is used in the field of hair, skin, nail care or traumatic infection.
Further, the hair care includes shampoo, hair conditioner or hair oil, hair wax, and the like.
Further, the skin care includes skin beauty improvement such as acne improvement, pore enlargement, anti-inflammation, moisture retention, wrinkle removal and aging resistance.
In some embodiments of the invention, the composition is used to repair acne or improve acne marks on the skin.
Further, the traumatic infection includes superficial abrasion, folliculitis, furuncle, acne, pimple, pustule, cyst, etc.
In a fourth aspect of the invention, there is provided a care product for acne or acne marks, said care product comprising a protamine-PDRN complex according to the first aspect.
Preferably, the care product is a gel or a serum.
In order to make the technical solutions of the present invention more clearly understood by those skilled in the art, the technical solutions of the present invention will be described in detail below with reference to specific embodiments.
The method used in the invention is a conventional production method if no special provisions are made; the raw materials used are all conventional commercial products; protamine, PDRN and functional polypeptides used in the following examples were produced by lukehui biotechnology (wih) limited; the palmitoyl tetrapeptide-7, the palmitoyl tripeptide-1, the carnosine, the tripeptide-1 and the copper peptide are prepared by a solid phase synthesis technology.
Example 1 construction of protamine-PDRN Complex
(1) Firstly, mixing a 20mg/L protamine solution and a 20mg/L PDRN solution according to the ratio of N/P being 1.5:1, and stirring for 1h at room temperature; (2) then standing the mixed solution for 1h at room temperature; (3) and finally, freeze-drying the mixed solution to obtain the protamine-PDRN compound.
Example 2 construction of protamine-PDRN Complex
(1) Firstly, mixing a 20mg/L protamine solution and a 20mg/L PDRN solution according to the ratio of N/P being 2.0:1, and stirring for 1h at room temperature; (2) then standing the mixed solution for 1h at room temperature; (3) and finally, freeze-drying the mixed solution to obtain the protamine-PDRN compound.
Example 3 construction of protamine-PDRN Complex
(1) Firstly, mixing a 20mg/L protamine solution and a 20mg/L PDRN solution according to the ratio of N/P being 2.5:1, and stirring for 1h at room temperature; (2) then standing the mixed solution for 1h at room temperature; (3) and finally, freeze-drying the mixed solution to obtain the protamine-PDRN compound.
Example 4 composition for treating acne and acne marks
In the embodiment, a composition for treating acne and acne marks is provided, and the components and the proportion of the composition are shown in table 1.
TABLE 1 formulation composition for the treatment of acne and acne marks
| Components | Specific gravity (%) |
| Carbomer | 0.6-0.9 |
| Triethanolamine | 0.5-0.9 |
| protamine-PDRN complex (example 1) | 0.1-0.8 |
| Palmitoyl tripeptide-1 | 0.002-0.02 |
| Nonapeptide-1 | 0.002-0.02 |
| Low molecular weight sodium acetyl hyaluronate | 0.05-0.1 |
| Nicotinamide | 0.5-6 |
| Tranexamic acid | 0.5-2 |
| Propylene glycol | 5-15 |
| Phenoxyethanol | 0.3-0.8 |
| Chlorophytidine ester | 0.03-0.1 |
| Sterilized purified water | Balance of |
Sterilizing purified water dispersed carbomer, adjusting pH to 5.5-7 with triethanolamine, sequentially adding the rest materials, and stirring to obtain composition in form of gel for treating acne and acne mark. The gel product was prepared according to the preparation method in the specific proportions described in table 2:
TABLE 2 formula of gel for treating acne and acne mark
Example 5 composition for treating acne and acne marks
In this embodiment, another composition for treating acne and acne marks is provided, wherein the composition ratio of each raw material is as shown in table 3.
TABLE 3 formulation composition of composition for treating acne and acne marks
| Components | Specific gravity (%) |
| Carbomer | 0.6-0.9 |
| Triethanolamine | 0.5-0.9 |
| protamine-PDRN complex (example 2) | 0.1-0.8 |
| Copper peptide | 0.002-0.02 |
| Nonapeptide-1 | 0.002-0.02 |
| Low molecular weight sodium acetyl hyaluronate | 0.05-0.1 |
| Nicotinamide | 0.5-6 |
| Tranexamic acid | 0.5-2 |
| Propylene glycol | 5-15 |
| Phenoxyethanol | 0.3-0.8 |
| Chlorophytidine ester | 0.03-0.1 |
| Sterilized purified water | Balance of |
Sterilizing purified water dispersed carbomer, adjusting pH to 5.5-7 with triethanolamine, sequentially adding the rest materials, and stirring to obtain composition in form of gel for treating acne and acne mark. According to the preparation method, the gel product is prepared according to the specific proportion in table 4:
TABLE 4 formula of gel for treating acne and acne mark
| Components | Specific gravity (%) |
| Carbomer | 0.7 |
| Triethanolamine | 0.5 |
| protamine-PDRN complex (example 2) | 0.3 |
| Copper peptide | 0.002 |
| Nonapeptide-1 | 0.002 |
| Low molecular weight sodium acetyl hyaluronate | 0.1 |
| Nicotinamide | 1.5 |
| |
2 |
| Propylene glycol | 8 |
| Phenoxyethanol | 0.48 |
| Chlorophytidine ester | 0.06 |
| Sterilized purified water | Balance of |
Example 6 composition for treating acne and acne marks
In this example, there is provided a further composition for treating acne and acne marks, the composition ratios being as shown in table 5, for example.
TABLE 5 formulation composition for treating acne and acne marks
Sterilizing and purifying the water-dispersed carbomer, adjusting the pH value to 5.5-7 by using triethanolamine, sequentially adding the rest raw materials, and uniformly stirring to obtain the acne and acne mark removing composition in the form of essence. The essence is prepared according to the preparation method, and the composition ratio of the essence is specifically shown in table 6:
table 6 formula composition of essence for treating acne and acne marks
| Components | Specific gravity (%) |
| Carbomer | 0.09 |
| Triethanolamine | 0.085 |
| protamine-PDRN complex (example 3) | 0.2 |
| Copper peptide | 0.002 |
| Nonapeptide-1 | 0.002 |
| Low molecular weight hyaluronan | 0.08 |
| |
1 |
| 1, 2-pentanediol | 5 |
| Glycerol | 5 |
| Phenoxyethanol | 0.5 |
| Chlorophytidine ester | 0.05 |
| Sterilized purified water | Balance of |
Example 7 skin sensitization test
50 healthy guinea pigs weighing 300 ± 25g were selected, in which 25 females and 25 males were randomly divided into 5 groups (10 total of 5 females and 5 males per group), group 1 was a blank control group, group 2 was a positive control group using 2, 4-dinitrochlorobenzene, group 3 was a test group using the composition of example 4 of the present invention, group 4 was a test group using the composition of example 5 of the present invention, group 5 was a test group using the composition of example 6 of the present invention, and 3cm × 3cm area of the back of each guinea pig was shaved and sterilized with 75% medical alcohol. 2, 4-dinitrochlorobenzene at a sensitization concentration of 1% was uniformly applied to the shaved back area of the positive control guinea pigs at 0d, 7d and 14d, respectively, the composition of example 4 in the amount of soybean grains was uniformly applied to the shaved back area of the 3 rd group guinea pigs, the composition of example 5 in the amount of soybean grains was uniformly applied to the shaved back area of the 4 th group guinea pigs, and the composition of example 6 in the amount of soybean grains was uniformly applied to the shaved back area of the 5 th group test group guinea pigs, while the blank control group was not treated at all, covered with gauze and fixed with tape for 6 hours. At 28d, 2, 4-dinitrochlorobenzene with an excitation concentration of 0.5% was uniformly applied to the shaved back area of the positive control guinea pigs, the composition of the present invention having a soybean particle size was uniformly applied to the shaved back area of the test guinea pigs, the blank control guinea pigs were not treated, and they were covered with gauze and fixed with a plastic film for 6 hours. The skin was observed to have erythema or edema and other allergic reactions at 6h, 24h, 48h and 72h, respectively.
Evaluating the skin sensitization test result according to an allergy test skin reaction rating table, wherein the guinea pigs in a positive control group have obvious red swelling or erythema phenomena, and the sensitization rate is 100%; and all guinea pigs of the blank control group and 3 test groups using the composition of the invention have no red swelling and erythema, skin irritation reaction is 0, and the skin has no allergy, which indicates that the composition of the invention has high use safety.
Example 8 Propionibacterium acnes growth inhibition assay
And (3) coating the diluted propionibacterium acnes liquid on 12 solid brain heart infusion medium plates, and dividing the 12 plates into 4 groups, wherein each group comprises 3 plates. One group is blank control group without any treatment; one was a test group, in which a small hole having a diameter of 5mm was punched at the center of each plate medium, and then 100. mu.l of the solution obtained in example 1, example 2 or example 3 step (1) after filtration through a 0.22 μm filter was added to each well, followed by culturing at 35 ℃ for 3 days under anaerobic conditions. The results show that the thalli are uniformly distributed on the whole plate on 3 plates of the blank control group, and bacteriostatic rings with the diameter of 1.5-1.8 cm appear on 9 plates of the test group at the positions of holes, which shows that the protamine-PDRN compound can obviously inhibit the growth of propionibacterium acnes.
Example 9 skin oil secretion control test
40 volunteers with 18-40 years old oily skin and facial skin with abundant oil secretion are selected, wherein 20 male volunteers and 20 female volunteers are randomly divided into 2 groups, 10 male volunteers and 10 female volunteers, one blank control group is selected, and the other blank control group is a test group. Each volunteer was compared with the other volunteers, and the oil control effect of the composition of example 6 was evaluated by applying the product to the face uniformly at 8 am and 8 pm each day. Each volunteer did not use any cosmetics or drugs on the facial skin one week prior to use of the product and did not use any cosmetics or drugs during the test period using the product of the present invention. The amount of oil and fat secretion from the face of the subject was measured using a SEBUMETER skin oil and fat tester before the use and after the 1 st week, after the 2 nd week, after the 3 rd week, and after the 4 th week, and the amount of change in oil and fat secretion was calculated, and the reduction in skin oil and fat secretion (%) was equal to (average skin oil and fat amount before the test-average skin oil and fat amount at the time of measurement)/average skin oil and fat amount before the test × 100%. The results are shown in fig. 1, in which the blank control group has no statistical difference in the amount of facial fat secretion variation during the period, while the average skin fat secretion of the test group is significantly reduced after 1 week of the product application, and the average skin fat secretion is reduced by 30% after 4 weeks of the product application.
EXAMPLE 10 human acne removal test
156 acne patients aged 14 to 24 were selected, 79 men and 87 women, and randomly divided into 13 groups of 12 patients each. Of 13 patients, 1 group was a control group (1.5 ml of deionized water was applied evenly to the face each time, twice after cleansing with a mild cleansing product every day, avoiding exposure to the sun), and the remaining 12 groups were test groups: of these, 6 groups were the test group using the composition of example 4 (the composition of the present invention of a size of soybean particles was uniformly applied to the face each time, the mild cleansing product was applied twice a day after cleansing the face, and exposure to the sun was avoided), and 6 groups were the test group using the composition of example 5 (the composition of the present invention of a size of soybean particles was uniformly applied to the face each time, the mild cleansing product was applied twice a day after cleansing the face in the morning and evening, and exposure to the sun was avoided), and all patients had no treatment for acne within one week before using the composition of the present invention, used only the skin mild cleansing product for the test period, did not use any cosmetics and skin care products, and did not use anti-inflammatory and bactericidal drugs.
All patients who use the product of the invention do not have adverse symptoms such as allergy during the use, the curative effect is evaluated after 1 week, 2 weeks, 3 weeks and 4 weeks of the use of the product, and the curative effect is defined as 4 grades by skin damage count (acne, pimple, pustule, cyst), namely: the reduction is more than or equal to 90 percent for curing, 60 to 89 percent for obvious effect, 20 to 59 percent for improvement, and the counting is less than 20 percent for ineffectiveness. The results of the measurement and analysis of the treatment effect by the skin tester imaging technique showed that facial acne was not significantly improved during the period of the placebo group and that the individual patients experienced an exacerbation of symptoms. As can be seen from fig. 2 and 3, the symptoms of all patients were reduced and improved in the test groups using the composition of example 4 and the composition of example 5 after 1 week using the composition of the present invention, wherein 26 patients were cured in the test group using the composition of example 4 and 32 patients were cured in the test group using the composition of example 5. The treatment effect of all patients after 4 weeks of using the composition of the invention reaches cure and significant effect, 65 patients in the test group using the composition of example 4 are cured, and the cure rate reaches 90.3%; 69 of the test groups using the composition of example 5 were cured, with a cure rate of 95.8%. The oil secretion of the skin of the patient is obviously reduced, pores shrink and become small, the skin color is changed from light red or dark red to normal, and the acne does not relapse within one year after all the patients stop using the product.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A protamine-PDRN complex, wherein the ratio of protamine to PDRN in the complex is 10:1 to 1: 10.
2. The protamine-PDRN complex of claim 1, wherein the PDRN molecular weight is 5 to 50 ten thousand;
or, the protamine is specifically one of monoprotamine, biprotamine and tripprotamine;
or, the ratio of protamine to PDRN is 1.5:1 to 2.5: 1.
3. The protamine-PDRN complex of claim 1, wherein said protamine-PDRN complex is prepared by the following method: mixing a protamine solution and a PDRN solution in proportion, stirring for a period of time to obtain a mixed solution, standing the mixed solution for a period of time, and drying to obtain the protamine-PDRN compound;
preferably, the stirring time is 0.8-2 h, and particularly preferably 1h or 1.5 h;
preferably, the mixed solution is placed in a room temperature condition for standing, wherein the room temperature condition is not any room temperature condition, and specifically means a temperature condition of 18-25 ℃ under a standard atmospheric pressure;
preferably, the mixed solution is kept stand for 0.8-1.2 h at room temperature;
preferably, the drying manner is one of but not limited to vacuum drying, spray drying, flow drying or freeze drying; more preferably, the drying is performed by freeze-drying.
4. A composition comprising at least protamine, PDRN and other functional polypeptides, wherein the protamine and PDRN are protamine-PDRN complexes according to any one of claims 1 to 3.
5. The composition of claim 4, wherein the functional polypeptide is one or more of but not limited to anti-wrinkle, anti-aging, repairing, whitening, anti-allergy, anti-inflammatory, and anti-oxidant polypeptide;
preferably, the functional polypeptide is any one or combination of any several of palmitoyl tetrapeptide-7, palmitoyl tripeptide-1, carnosine, tripeptide-1, copper peptide and nonapeptide-1.
6. The composition as claimed in claim 4, further comprising other active ingredients, wherein the active ingredients comprise one or more of a moisturizing ingredient, a pH regulator, a whitening ingredient, a bacteriostatic ingredient, a cosmetic additive, a solubilizer and a surfactant;
preferably, the composition further comprises the following components: carbomer, triethanolamine, low molecular weight hyaluronan, nicotinamide, tranexamic acid, propylene glycol, 1, 2-pentanediol, glycerol, phenoxyethanol, chlorphenesin, or sterile purified water.
7. The composition of claim 6, wherein the composition comprises the following components in parts by weight: the addition amount of carbomer is 0.6-0.9%, the addition amount of triethanolamine is 0.5-0.9%, the addition amount of protamine-PDRN compound is 0.05-2%, the addition amount of anti-inflammatory polypeptide is 0.005-0.2%, the addition amount of low molecular weight hyaluronan is 0.05-0.1%, the addition amount of nicotinamide is 0.5-4%, the addition amount of tranexamic acid is 0.5-2%, the addition amount of 1, 2-pentanediol is 3-5%, the addition amount of glycerol is 2-12%, the addition amount of phenoxyethanol is 0.3-0.8%, and the addition amount of chlorphenesin is 0.03-0.1%.
8. Use of a composition according to any one of claims 4 to 7 in the manufacture of a skin care product.
9. Use of the composition of claim 8 in the preparation of a skin care product, wherein the skin care product is one or more of, but not limited to, an emulsion, a serum, a lotion, a cream, a powder, a cream, a gel, and a dressing;
or, the skin care product is used in the field of hair, skin, nail care or traumatic infection;
preferably, the hair care includes shampoos, conditioners or oils, hair waxes;
preferably, the skin care comprises skin beauty such as acne improvement, pore enlargement, anti-inflammation, moisture retention, wrinkle removal and aging resistance;
further, the composition is applied to repair acne or improve skin acne marks;
further, the traumatic infection includes superficial abrasion, folliculitis, furuncle, acne, pimple, pustule, cyst.
10. A care product for acne or acne marks comprising the protamine-PDRN complex of any of claims 1 to 3;
preferably, the care product is a water agent, an emulsion or an ointment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110436323.5A CN113332162B (en) | 2021-04-22 | 2021-04-22 | protamine-PDRN compound, composition and application in preparation of skin care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110436323.5A CN113332162B (en) | 2021-04-22 | 2021-04-22 | protamine-PDRN compound, composition and application in preparation of skin care product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113332162A true CN113332162A (en) | 2021-09-03 |
| CN113332162B CN113332162B (en) | 2022-03-29 |
Family
ID=77468365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110436323.5A Active CN113332162B (en) | 2021-04-22 | 2021-04-22 | protamine-PDRN compound, composition and application in preparation of skin care product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113332162B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113577243A (en) * | 2021-07-14 | 2021-11-02 | 润辉生物技术（威海）有限公司 | Active polypeptide-PDRN composition and application thereof in preparation of nursing products |
| CN115337321A (en) * | 2022-07-06 | 2022-11-15 | 山东省循证医学研究院 | Antidepressant composition containing polydeoxyribonucleotide and medicine |
| CN115737470A (en) * | 2022-11-25 | 2023-03-07 | 润辉生物技术（威海）有限公司 | carnosine-PDRN compound and preparation method and application thereof |
| WO2023076840A1 (en) * | 2021-10-28 | 2023-05-04 | Dr. J Skinclinic, Inc. | Topical composition comprising retinol and pdrn and use of same |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07115950A (en) * | 1993-10-27 | 1995-05-09 | Asama Kasei Kk | Preservative for food |
| US6036966A (en) * | 1998-02-17 | 2000-03-14 | Youssefyeh; Rena T. | Skin treatment compositions comprising protein and enzyme extracts |
| CN1596127A (en) * | 2001-10-09 | 2005-03-16 | 英属哥伦比亚大学 | Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| EP1997477A1 (en) * | 2007-05-31 | 2008-12-03 | FUJIFILM Corporation | Anti-acne skin agent for external use |
| CN103655431A (en) * | 2012-09-03 | 2014-03-26 | 爱德芳世株式会社 | Cosmetic and make-up method |
| CN107287186A (en) * | 2016-04-05 | 2017-10-24 | 达特珂贝怡股份有限公司 | Polydeoxyribonucleotide for separate the method for polydeoxyribonucleotide from the seminal fluid of fish, obtaining by methods described and application thereof |
| CN111836617A (en) * | 2018-03-08 | 2020-10-27 | 医药研究产品有限公司 | Liquid composition containing a mixture of DNA fragments at a high concentration and having fluidity, and method for producing same |
| CN112656701A (en) * | 2020-12-30 | 2021-04-16 | 王超云 | Whitening and freckle-removing composition containing PDRN and application thereof |
-
2021
- 2021-04-22 CN CN202110436323.5A patent/CN113332162B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07115950A (en) * | 1993-10-27 | 1995-05-09 | Asama Kasei Kk | Preservative for food |
| US6036966A (en) * | 1998-02-17 | 2000-03-14 | Youssefyeh; Rena T. | Skin treatment compositions comprising protein and enzyme extracts |
| CN1596127A (en) * | 2001-10-09 | 2005-03-16 | 英属哥伦比亚大学 | Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| EP1997477A1 (en) * | 2007-05-31 | 2008-12-03 | FUJIFILM Corporation | Anti-acne skin agent for external use |
| CN103655431A (en) * | 2012-09-03 | 2014-03-26 | 爱德芳世株式会社 | Cosmetic and make-up method |
| CN107287186A (en) * | 2016-04-05 | 2017-10-24 | 达特珂贝怡股份有限公司 | Polydeoxyribonucleotide for separate the method for polydeoxyribonucleotide from the seminal fluid of fish, obtaining by methods described and application thereof |
| CN111836617A (en) * | 2018-03-08 | 2020-10-27 | 医药研究产品有限公司 | Liquid composition containing a mixture of DNA fragments at a high concentration and having fluidity, and method for producing same |
| CN112656701A (en) * | 2020-12-30 | 2021-04-16 | 王超云 | Whitening and freckle-removing composition containing PDRN and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| MI YUA ET AL: "Polydeoxyribonucleotide Improves Wound Healing of Fractional Laser Resurfacing in Rat Model", 《JOURNAL OF COSMETIC AND LASER THERAPY》 * |
| 姜海燕 等: "多聚脱氧核糖核苷酸对面部毛孔粗大改善的临床观察", 《中国医疗美容》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113577243A (en) * | 2021-07-14 | 2021-11-02 | 润辉生物技术（威海）有限公司 | Active polypeptide-PDRN composition and application thereof in preparation of nursing products |
| WO2023076840A1 (en) * | 2021-10-28 | 2023-05-04 | Dr. J Skinclinic, Inc. | Topical composition comprising retinol and pdrn and use of same |
| CN115337321A (en) * | 2022-07-06 | 2022-11-15 | 山东省循证医学研究院 | Antidepressant composition containing polydeoxyribonucleotide and medicine |
| CN115737470A (en) * | 2022-11-25 | 2023-03-07 | 润辉生物技术（威海）有限公司 | carnosine-PDRN compound and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113332162B (en) | 2022-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113332162B (en) | protamine-PDRN compound, composition and application in preparation of skin care product | |
| CN113117137A (en) | Medical dressing containing recombinant human collagen and preparation method thereof | |
| WO2003011303A1 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
| AU2002317053A1 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
| JP6894991B2 (en) | Cosmetic composition containing mint vinegar as an active ingredient | |
| CN109276523A (en) | A kind of peppermint facial mask liquid and preparation method thereof | |
| EP1527770B1 (en) | A cosmetic mask composition | |
| CN111494282B (en) | Red-removing anti-inflammatory oil-controlling acne-removing composition, application thereof and acne-removing balancing essence containing composition | |
| CN111743830A (en) | Acne-removing composition and application thereof | |
| KR102292975B1 (en) | Cosmetic materials composition for skin anti-wrinkling and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof | |
| CN111671692A (en) | Acne-removing composition and preparation method and application thereof | |
| CN114748367A (en) | Moisturizing repair essence and preparation method thereof | |
| KR101292274B1 (en) | Cosmetic composition for anti-wrinkle | |
| CN111743826A (en) | Freckle-removing, wrinkle-resisting and moisturizing emulsion | |
| CN112022795A (en) | Skin care and repair composition, preparation method and application thereof | |
| CN111991309A (en) | Composition with repairing and moisturizing effects and preparation method and application thereof | |
| CN108078868B (en) | Antiallergic composition for skin care products | |
| CN113274337A (en) | Medical skin repairing and nursing film and preparation method thereof | |
| CN111529460A (en) | Mask composition, mask and preparation method of mask | |
| KR20090028275A (en) | Cosmetic materials for anti-aging and winkle reducing effects having essential oil complex as its principal ingredient, and the manufacturing method thereof | |
| CN108578265A (en) | Maintenance stoste and its preparation method and application | |
| CN108721136A (en) | Maintenance gel and its preparation method and application | |
| CN107789277A (en) | A kind of hyaluronic acid lip composition and preparation method with multi-efficiency | |
| EP4070798A1 (en) | Chronic wound healing composition and application thereof | |
| CN117298026A (en) | Composition and liposome with skin care effect, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A fish protein PDRN complex, composition, and its application in the preparation of skincare products Granted publication date: 20220329 Pledgee: Shandong Wendeng Rural Commercial Bank Co.,Ltd. Pledgor: REALI TIDE BIOLOGICAL TECHNOLOGY (WEIHAI) Co.,Ltd. Registration number: Y2024980006150 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |